Earnings call transcript: Washington Trust beats Q3 2026 estimates as stock rises 6.5%

Washington Trust reported Q3 net income of $19.4 million, net interest income up 15% year over year to $44.7 million, and net interest margin up 44 bps year over year to 284 bps; shares were indicated 6.5% higher premarket at $38.97. The article cites EPS of $2.50 versus $0.87 expected, but the included earnings-call transcript states net income was $19.4 million, or $1.01 per share—a material inconsistency in the source. Management guided to Q4 NIM of 285–290 bps and expenses about $1.5 million above Q3, while saying it has no current share-repurchase plans and will prioritize growth investments.

Analysis

The first-order signal is positive, but the headline EPS beat is not tradeable until reconciled: the article cites $2.50 EPS, while the supplied call transcript reports $19.4 million of net income, or $1.01 per share. That changes the apparent surprise from extraordinary to a more ordinary beat versus $0.87. Treat the premarket move as vulnerable to a data correction; verify the filed release and market data before sizing WASH.

Underlying earnings momentum is real but less clean than the headline suggests. NIM guidance of 285–290 bp supports near-term carry, yet the quarter included a BOLI gain, derivative income, prior-quarter loan interest, and a swap benefit. Over 1–3 months, watch whether deposit growth keeps pace with targeted loan growth without renewed wholesale funding or deposit-cost pressure. Over 6–18 months, branch spending and commercial growth could dilute returns if competitive CRE spreads compress; buybacks are not a near-term support, and management acknowledged GAAP capital is relatively light versus peers.

Credit improvement is not a blanket de-risking signal: the office resolution included a charge-off, while office/lab exposures remain under review. The contrarian risk is that investors capitalize peak margin expansion as durable earnings growth just as loan competition and branch costs rise. A sustained NIM above guidance, stable funding costs, and improving criticized assets would weaken that concern.

Key Decisions for Investors

• Do not chase the premarket gap until the $2.50 versus $1.01 EPS discrepancy is reconciled against the filed release; it is the key near-term catalyst and may invalidate the reported surprise.
• If verified results support only the transcript’s $1.01 EPS, consider a small tactical short only if WASH fails to hold the $36.59 prior close after the gap; use a move above the reported $40.54 52-week high as a risk trigger. Avoid the trade if the release confirms $2.50 or the stock holds the gap.
• For a 1–3 month long thesis, wait for evidence that Q4 NIM reaches the 285–290 bp guide while deposits fund loan growth and wholesale funding stays contained; reassess if deposit costs rise or NIM misses guidance.
• Track office/lab criticized and non-accrual balances, provision expense, and the next-quarter branch expense run rate. Rising problem assets or expense growth without corresponding revenue would falsify the operating-leverage thesis.